ABBV AbbVie Inc.
Company Analysis
Latest News
🔴 AbbVie is trading 3.3% down today after recent dividend-hike rally
ABBV is trading 3.3% down at $225.81, experiencing a pullback and profit-taking following a sharp multi-day run-up that saw the stock climb above $230. * No...
AbbVie lowers Q4 and FY25 EPS guidance due to a $1.3 billion R&D expense.
AbbVie updated its Q4 and full-year 2025 earnings guidance to reflect a significant expense related to acquired in-process research and development (IPR&D)....
AbbVie Reportedly in Advanced Talks to Acquire Oncology Firm Revolution Medicines
AbbVie is in advanced discussions to acquire Revolution Medicines, according to a report from The Wall Street Journal. Revolution Medicines specializes in...
🟢 ABBV is trading 3.65% up today after UBS price target hike
ABBV is trading at $232.10 (+3.65%), following UBS raising its price target to $240 from $220. * The stock builds on yesterday's close of $223.93 (+1.70%)...
AbbVie Bolsters Oncology Pipeline with Over $1.1B Lung Cancer Drug Deal
AbbVie Inc. significantly expanded its oncology pipeline by securing ex-China rights to Zejing Biopharmaceutical's late-stage lung cancer drug, ZG006...
AbbVie Stock Declines Nearly 4% Following Recent Strategic and Financial Updates
AbbVie's stock decreased 3.98% on the previous trading day, closing at $220.18. This movement follows a series of recent company developments and strategic...
🔴 ABBV is trading 4.7% down today
ABBV is trading at $218.60 (-4.67%), diverging sharply from broader market gains as no specific news or event explains the sudden decline. The decline...
🔴 ABBV is trading 4% down today
ABBV is trading at -4.02% now at $220.09 as the stock experiences an unexplained drop ahead of a routine J.P. Morgan Healthcare Conference presentation. * ...
🔴 ABBV is trading 4% down today
ABBV is trading at $220.09 (-4.02%), experiencing a significant drop without clear company-specific catalysts or news identified for the session. * The...
AbbVie Enters Licensing Deal with Zelgen Biopharma for Cancer Drug Alveltamig
AbbVie partnered with Zelgen Biopharma to develop and commercialize Alveltamig. The drug is currently under investigation as a treatment for various blood...
Court Blocks US 340B Drug Rebate Program, Impacting AbbVie and Other Drugmakers
A federal judge issued a preliminary injunction, temporarily blocking the U.S. government’s 340B Rebate Model Pilot Program. The program was scheduled to...
AbbVie Sees December Analyst Upgrades Amidst Pipeline Progress and Drug Pricing Scrutiny
AbbVie entered December 30, 2025, following a strong year, buoyed by positive analyst sentiment in December with upgrades from HSBC and Morgan Stanley raising...
AbbVie Awaits Imminent U.S. Drug Pricing Deal Post-Holidays
The primary focus for AbbVie on December 27, 2025, centers on the anticipated drug-pricing deal with the U.S. government. Reports from December 22 and December...
AbbVie Terminates ABBV-303 Oncology Study Ahead of Q3 Earnings
On October 24, 2025, AbbVie terminated its Phase 1 clinical trial of ABBV-303 for advanced solid tumors, a move that may affect its oncology pipeline and...
AbbVie Secures Rinvoq Exclusivity until 2037 Through Legal Settlements
AbbVie has reached legal settlements that will delay the market entry of generic versions of its key immunology drug, Rinvoq, until 2037. This development...
AbbVie's Investigational Kidney Disease Therapy Receives FDA Fast Track Designation
AbbVie, in collaboration with Calico Life Sciences, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to...
AbbVie CEO Supports Potential US Probe into Foreign Drug Pricing
AbbVie's CEO, Robert Michael, has voiced support for potential new U.S. trade measures aimed at foreign drug pricing. His comments came as reports emerged that...
AbbVie's Rinvoq Shows Superiority Over Humira in Head-to-Head Rheumatoid Arthritis Study
AbbVie announced positive topline results from its Phase 3b/4 SELECT-SWITCH study, a head-to-head trial comparing Rinvoq (upadacitinib) to Humira (adalimumab)...
AbbVie completes Bretisilocin acquisition; FDA expands RINVOQ label
On October 17, 2025, AbbVie announced the completion of its acquisition of Gilgamesh Pharmaceuticals' Bretisilocin, a move seen as strengthening its...
ABBV edges lower as investors digest strong Q2 earnings and guidance hike
AbbVie Inc. closed at $226.22 on October 15, 2025, down 1.27% from the previous session, continuing a modest decline over the past week despite strong business...